Table 4. Effect of cART on CD4+ T-cell count, CD4/CD8 ratio and HIV viral load in HIV-HBV and HIV-HCV coinfection.
| Groups | cART regimen | CD4+ T-cell count (cells/mm3) median (IQR) |
p-value | CD4/CD8 ratio median (IQR) |
p-value | Log HIV Viral load (copies/ml) median (IQR) | p-value | CD4+ T-cell count (cells/mm3) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| < 200 n (%) | 200–500 n (%) | > 500 n (%) | p-value | ||||||||
| HIV-HBV |
Pre-cART |
316 (227–466) | 0.005a | 0.30 (0.19–0.59) | 0.024a | 4.25 (2.65–5.10) | < 0.001a | 5 (20.84) | 15 (62.50) | 4 (16.66) | 0.026a |
| HIV-HCV | 304 (154–478) | 0.085a | 0.32 (0.16–0.47) | 0.035a | 4.05 (1.70–5.35) | < 0.001a | 6 (26.09) | 13 (56.52) | 4 (17.39) | 0.118a | |
| HIV-HBV + HIV-HCV | 312 (202–467) | 0.004a | 0.30 (0.17–0.50) | 0.006a | 3.56 (1.70–4.21) | < 0.001a | 11 (23.41) | 28 (59.57) | 8 (17.02) | 0.006a | |
| HIV-HBV |
On-cART (12 months) |
512 (346–613) | 0.042b | 0.48 (0.30–0.70) | 0.051b | 1.70 (1.70–1.90) | 0.012b | 1 (4.17) | 11 (45.83) | 12 (50.00) | 0.482b |
| HIV-HCV | 344 (252–556) | 0.008b | 0.48 (0.29–0.56) | 0.045b | 1.70 (1.70–1.70) | 0.076b | 1 (4.35) | 16 (69.57) | 6 (26.08) | 0.219b | |
| HIV-HBV + HIV-HCV | 435 (266–569) | 0.007b | 0.48 (0.29–0.63) | 0.008b | 1.70 (1.70–1.78) | 0.004b | 2 (4.26) | 27 (57.45) | 18 (38.29) | 0.172b | |
| HIV-HBV |
On-cART (24 months) |
613 (423–748) | < 0.001c | 0.66 (0.48–0.89) | < 0.001c | 1.70 (1.40–1.70) | < 0.001c | 1 (4.17) | 7 (29.17) | 16 (66.66) | 0.020c |
| HIV-HCV | 485 (406–561) | < 0.001c | 0.50 (0.43–0.71) | 0.002c | 1.70 (1.40–1.70) | < 0.001cc | 0 (0.00) | 12 (52.17) | 11 (47.83) | 0.010c | |
| HIV-HBV + HIV-HCV | 554 (406–662) | < 0.001c | 0.61 (0.46–0.86) | < 0.001c | 1.70 (1.40–1.70) | < 0.001c | 1 (2.13) | 19 (40.43) | 27 (57.44) | < 0.001c | |
cART, combination antiretroviral therapy; HIV, human immunodeficiency virus; HBV, hepatitis B virus; HCV, hepatitis C virus; n, number of patients; IQR, interquartile range
ap-value for baseline versus 12 months on-cART
bp-value for 12 versus 24 months on-cART
cp-value for baseline versus 24 months on-cART.